Type 1 Diabetes - January 2021
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Type 1 Diabetes - January 2021
Adocia files patent for its innovative hydrogel scaffold cell therapy for the treatment of Type 1 Diabetes
11 Jan 2020
Hydrogel scaffold (β-cell therapy) – Adocia
- Adocia has filed a patent for a hydrogel scaffold that hosts and protects pancreatic β cells for replacement of the missing cells of people with Type 1 Diabetes
- This hydrogel scaffold contains pancreatic cells that could restore glycemic control without requiring insulin injection and immunosuppressant drugs while protecting them from an immune reaction
- The objective is to use a human Langerhans islet to achieve the proof of concept of a safe and effective implant. Following this, the company will engineer pancreatic β cells from stem cells to overcome the limited number of donors
- Academic collaboration with Pr. Pattou’s Inserm team has been established to develop this product in animal models and ultimately in human
Overcoming the current limitations of cell therapy, Adocia’s hydrogel scaffold cell therapy can benefit a larger population with T1D
Share this
CI Scientists Remarks:
- Adocia has added a fourth preclinical program, hydrogel scaffold for cell therapy in its pipeline for the treatment of T1D. Earlier three preclinical products being bi-hormonal products (BioChaperone LisPram, BioChaperone AsPram, and BioChaperone GlaLira)
- This hydrogel-based scaffold is designed to host and protect β cells for up to 3 years. Implantation will be carried out through intra-peritoneal or subcutaneous sites and is also retrievable
- Keeping in mind the limitations with the current cell therapies (limited donors and need for immunosuppressive drugs), Adocia has developed this scaffold protecting them from an immune reaction
- In-vivo studies in rabbits were well tolerated
- Adocia’s plan of development:
- To conduct studies in small animals in Q2’21
- To establish proof of concept in large animals in Q4’21
- To initiate Phase 1 clinical trials in 2022
– Dr. Kowndinya, CI Scientists